Section of Nutrition Research, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, South Kensington Campus, London SW7 2AZ, United Kingdom.
The National Phenome Centre, Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London W12 0NN, United Kingdom.
J Pharm Biomed Anal. 2022 Nov 30;221:115060. doi: 10.1016/j.jpba.2022.115060. Epub 2022 Sep 15.
Short-chain carboxylic acids (SCCAs) produced by gut microbial fermentation may reflect gastrointestinal health. Their concentrations in serum and urine are indicative of specific metabolic pathway activity; therefore, accurate quantitation of SCCAs in different biofluids is desirable. However, it is often challenging to quantitate SCCAs since matrix effects, induced by the presence of a vast variety of other compounds other than SCCAs in complex biofluids, can suppress or enhance signals. Materials used for sample preparation may introduce further analytical challenges. This study reports for the first time a LC-MS/MS-based method to quantitate ten SCCAs (lactate, acetate, 2-hydroxybutyrate, propionate, isobutyrate, butyrate, 2-methylbutyrate, isovalerate, valerate and hexanoate) and evaluates the matrix effects in five human biofluids: serum, urine, stool, and contents from the duodenum and intestinal stoma bags. The optimized method, using 3-Nitrophenylhydrazone as a derivatization agent and a Charge Surface Hybrid reverse phase column, showed clear separation for all SCCAs at a concentration range of 0.1-100 µM, in a 10.5 min run without carry-over effects. The validation of the method showed a good linearity (R2 > 0.99), repeatability (CV ≤ 15%) assessed by intra- and inter-day monitoring. The lowest limit of detection (LLOD) was 25 nM and lowest limit of quantitation (LLOQ) was 50 nM for nine SCCA except acetate at 0.5 and 1 µM, respectively. Quantitative accuracy in all biofluids for most compounds was < ±15%. In summary, this methodology has the advantages over other techniques for its simple and fast sample preparation and a high level of selectivity, repeatability and robustness for SCCA quantification. It also reduced interferences from the matrix or sample containers, making it ideal for use in high-throughput analyses of biofluid samples from large-scale studies.
短链羧酸(SCCAs)是肠道微生物发酵产生的,可能反映胃肠道健康。它们在血清和尿液中的浓度反映了特定代谢途径的活性;因此,准确地定量不同生物流体中的 SCCA 是可取的。然而,由于 SCCA 以外的其他化合物的存在会产生基质效应,从而抑制或增强信号,因此定量 SCCA 通常具有挑战性。用于样品制备的材料可能会带来进一步的分析挑战。本研究首次报道了一种基于 LC-MS/MS 的方法,用于定量十种 SCCA(乳酸、乙酸、2-羟基丁酸、丙酸、异丁酸、丁酸、2-甲基丁酸、异戊酸、戊酸和己酸),并评估了五种人体生物流体中的基质效应:血清、尿液、粪便以及十二指肠和肠造口袋内容物。该优化方法使用 3-硝基苯腙作为衍生化试剂和电荷表面杂化反相柱,在 10.5 分钟的运行时间内,无拖尾效应,在 0.1-100µM 的浓度范围内对所有 SCCA 均能实现清晰分离。该方法的验证结果表明,线性良好(R2>0.99),日内和日间监测的重复性(CV≤15%)良好。除乙酸外,除乙酸外,9 种 SCCA 的最低检测限(LLO D)为 25nM,最低定量限(LLOQ)为 50nM,分别为 0.5 和 1µM。在大多数生物流体中,大多数化合物的定量准确性均<±15%。总之,与其他技术相比,该方法具有样品制备简单快速、SCCA 定量具有高选择性、重复性和稳健性等优点。它还减少了基质或样品容器的干扰,使其成为高通量分析大型研究中生物流体样品的理想选择。